New hope for stubborn high cholesterol: experimental drug SHR-1918 enters trials
NCT ID NCT07404553
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SHR-1918 for people with high cholesterol that remains high even when taking statins and another type of cholesterol-lowering drug (PCSK9 inhibitors). About 126 adults will receive either SHR-1918 or a placebo to see if it safely lowers their LDL or 'bad' cholesterol after 12 and 24 weeks. The goal is to offer a new option for those who need better cholesterol control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing First Hospital
RECRUITINGNanjing, Jiangsu, 210006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily pill help kids with inherited high cholesterol?
- Free meds and tailored education may cut heart risks in Low-Income seniors
- Can a smartphone app help lower bad cholesterol?
- New cholesterol drug candidate tested in healthy volunteers
- New cholesterol drugs show promise in Late-Stage trial
- New hope for stubborn high cholesterol: pemafibrate trial launches